These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 39026980)

  • 1. The efficacy and safety of immunotherapy as first-line treatment for extensive-stage small cell lung cancer: evaluating based on reconstructed individual patient data.
    Zhang S; Li S; Cheng Y
    Front Oncol; 2024; 14():1371313. PubMed ID: 39026980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of PD-1/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small cell lung cancer: A systematic review and meta-analysis.
    Zhang S; Li S; Cheng Y
    Thorac Cancer; 2020 Dec; 11(12):3536-3546. PubMed ID: 33058504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer.
    Yu H; Chen P; Cai X; Chen C; Zhang X; He L; Zhou Y; Hong S; Zhang B
    Cancer Immunol Immunother; 2022 Mar; 71(3):637-644. PubMed ID: 34297160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of anti-PD-1 inhibitor versus anti-PD-L1 inhibitor in first-line treatment of extensive-stage small cell lung cancer: a multicenter retrospective study.
    Qin B; Xin L; Liang C; Li L; Song Q; Long Y; Zhang X; Wang D; Shi W; Zhang J; Hu Y; Yang B; Xiong Q
    BMC Cancer; 2024 Jan; 24(1):100. PubMed ID: 38233798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and safety of anlotinib plus anti-programmed cell death 1/ligand 1 (anti-PD-1/PD-L1) antibodies as maintenance therapy after first-line chemotherapy combined with anti-PD-1/PD-L1 antibodies in extensive-stage small cell lung cancer: a real-world study.
    Yang P; Luo H; Zhao L; Xiong F; Tang C
    J Thorac Dis; 2024 Jul; 16(7):4391-4399. PubMed ID: 39144292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of first-line immunotherapy plus chemotherapy in treating patients with extensive-stage small cell lung cancer: a Bayesian network meta-analysis.
    Zhang T; Li W; Diwu D; Chen L; Chen X; Wang H
    Front Immunol; 2023; 14():1197044. PubMed ID: 37435087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety comparison of PD-1 inhibitors
    Yang G; Sun H; Sun N; Huang W; Wang Z; Zhang H; Liu C
    J Thorac Dis; 2022 Dec; 14(12):4925-4937. PubMed ID: 36647464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of efficacy and safety between PD-1 inhibitors and PD-L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysis.
    Wang Y; Li L; Hu J; Zhao Y; Yan H; Gao M; Yang X; Zhang X; Ma J; Dai G
    BMC Cancer; 2023 Dec; 23(1):1196. PubMed ID: 38057736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of first-line immune checkpoint inhibitors for patients with extensive-stage small cell lung carcinoma: A systematic review and network meta-analysis.
    Du J; Wang X; Fan L; Shan X; Li M; Liu L
    Heliyon; 2023 Apr; 9(4):e14794. PubMed ID: 37095958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of first-line PD-1/PD-L1 inhibitor combinations for extensive-stage small-cell lung cancer: a Bayesian network meta-analysis.
    Li H; Han H; Li C; Wu R; Wang Z; Wang Y; Zhan P; Lv T; Zhang F; Song Y; Liu H
    Ther Adv Med Oncol; 2023; 15():17588359231189430. PubMed ID: 37885460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-analysis.
    Zhou T; Zhang Z; Luo F; Zhao Y; Hou X; Liu T; Wang K; Zhao H; Huang Y; Zhang L
    JAMA Netw Open; 2020 Oct; 3(10):e2015748. PubMed ID: 33074323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining PD-1 or PD-L1 inhibitors with chemotherapy is a good strategy for the treatment of extensive small cell lung cancer: A retrospective analysis of clinical studies.
    Luo H; Song G; Wang D; Li M; Dai N
    Front Immunol; 2022; 13():1059557. PubMed ID: 36544769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of first-line PD-L1/PD-1 inhibitors in limited-stage small cell lung cancer: a multicenter propensity score matched retrospective study.
    Xie J; Xu K; Cai Z; Chen M; Jiang Y; Ye J; Lin X; Lv T; Zhan P
    Transl Lung Cancer Res; 2024 Mar; 13(3):526-539. PubMed ID: 38601454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis.
    Li Y; Liang X; Li H; Chen X
    Chin Med J (Engl); 2023 Sep; 136(18):2156-2165. PubMed ID: 37596898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of PD-L1 Inhibitors plus Chemotherapy versus Chemotherapy Alone in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer: A Retrospective Real-World Study.
    Qu J; Kalyani FS; Shen Q; Yang G; Cheng T; Liu L; Zhou J; Zhou J
    J Oncol; 2022; 2022():3645489. PubMed ID: 36199793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of immune checkpoint inhibitors plus platinum-etoposide
    Chen Y; Shang H; Yang Y; Wang Q; Gao X; Huang G
    Transl Cancer Res; 2024 Aug; 13(8):4146-4158. PubMed ID: 39262463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the profiles of first-line PD-1/PD-L1 inhibitors for advanced NSCLC lacking driver gene mutations: a systematic review and Bayesian network meta-analysis.
    Wenfan F; Manman X; Xingyuan S; Zeyong J; Jian Z; Lu D
    Ther Adv Chronic Dis; 2023; 14():20406223231189224. PubMed ID: 37841212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune-checkpoint inhibitors plus chemotherapy versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer.
    Zhou F; Zhao W; Gong X; Ren S; Su C; Jiang T; Zhou C
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32900864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of novel immune checkpoint inhibitor-based combinations versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer: A network meta-analysis.
    Yang C; Xuan T; Gong Q; Dai X; Wang C; Zhang R; Zhao W; Wang J; Yue W; Li J
    Thorac Cancer; 2024 May; 15(15):1246-1262. PubMed ID: 38623838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of PD-1/PD-L1 Inhibitors versus Chemotherapy in Lung Cancer with Brain Metastases: A Systematic Review and Meta-Analysis.
    Yang X; Zeng Y; Tan Q; Huang Z; Jia J; Jiang G
    J Immunol Res; 2022; 2022():4518898. PubMed ID: 35637793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.